Source: actasanitaria.com Researchers from the Health Research Institute of the Hospital Clínico de Valencia (INCLIVA) have shown that a molecule used to treat cancer, called PD033299, […]

Source: redaccionmedica.com The great results obtained with CAR-T therapies in cancer patients in whom chemotherapy has failed have focused the day ‘Towards a greater knowledge of […]

Source: redaccionmedica.com AstraZeneca has presented new analyzes of the Pegasus-Timi 54 trial in the framework of the Scientific Conferences of the American Heart Association. These findings […]

Source: actasanitaria.com A day after knowing the draft agreement on Brexit that last Tuesday, November 13, reached the European Union (EU) and the British Government, the […]

Source: actasanitaria.com The European Commission has approved a new indication of enzalutamide, a drug whose trade name is Xtandi and which was registered by the pharmaceutical […]

Source: actasanitaria.com In order to highlight the priorities of the sector when there are just over seven months left for the next European elections, a manifesto, […]

Source: actasanitaria.com The Spanish Agency for Medicines and Health Products (AEMPS) has published the news regarding the submission of requests for regulatory activities of medicines for […]

Source: redaccionmedica.com The government has approved this Tuesday for 9.550.000 euros to attend the 2019 call for grants of the Strategic Plan for Research and Innovation […]

Source: immedicohospitalario.es Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized according to the most recent results of […]

Source: redaccionmedica.com The biopharmaceutical company Gilead Sciences continues its commitment to research in our country, this time, developing a project to achieve the cure of HIV. […]

Source: redaccionmedica.com Currently, the pharmaceutical industry has a total of 169 new drugs against breast cancer in the clinical research phase, a disease that encompasses the […]

Source: redaccionmedica.com Actelion Pharmaceuticals has announced the results of the first randomized controlled trial in portopulmonary hypertension (HTPP). This study has shown that Opsumit (macitentan) significantly […]